KR101299321B1 - 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법 - Google Patents

4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법 Download PDF

Info

Publication number
KR101299321B1
KR101299321B1 KR1020087002421A KR20087002421A KR101299321B1 KR 101299321 B1 KR101299321 B1 KR 101299321B1 KR 1020087002421 A KR1020087002421 A KR 1020087002421A KR 20087002421 A KR20087002421 A KR 20087002421A KR 101299321 B1 KR101299321 B1 KR 101299321B1
Authority
KR
South Korea
Prior art keywords
delete delete
formula
compound
reaction
amino
Prior art date
Application number
KR1020087002421A
Other languages
English (en)
Korean (ko)
Other versions
KR20080039392A (ko
Inventor
조지 더블유. 뮬러
마노하르 티. 사인다네
촨솅 게
로저 첸
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37305020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101299321(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20080039392A publication Critical patent/KR20080039392A/ko
Application granted granted Critical
Publication of KR101299321B1 publication Critical patent/KR101299321B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020087002421A 2005-06-30 2006-06-29 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법 KR101299321B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69622405P 2005-06-30 2005-06-30
US60/696,224 2005-06-30
PCT/US2006/026210 WO2007005972A1 (en) 2005-06-30 2006-06-29 Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137003558A Division KR101342241B1 (ko) 2005-06-30 2006-06-29 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법

Publications (2)

Publication Number Publication Date
KR20080039392A KR20080039392A (ko) 2008-05-07
KR101299321B1 true KR101299321B1 (ko) 2013-08-26

Family

ID=37305020

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137003558A KR101342241B1 (ko) 2005-06-30 2006-06-29 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법
KR1020087002421A KR101299321B1 (ko) 2005-06-30 2006-06-29 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137003558A KR101342241B1 (ko) 2005-06-30 2006-06-29 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법

Country Status (25)

Country Link
US (5) US7994327B2 (xx)
EP (2) EP1907373B1 (xx)
JP (2) JP5366544B2 (xx)
KR (2) KR101342241B1 (xx)
CN (2) CN102643267B (xx)
AU (1) AU2006265019B2 (xx)
BR (1) BRPI0612803A2 (xx)
CA (2) CA2612612C (xx)
CR (1) CR9697A (xx)
DK (2) DK1907373T3 (xx)
EC (1) ECSP088154A (xx)
ES (2) ES2430545T3 (xx)
HK (2) HK1121447A1 (xx)
HR (2) HRP20130102T1 (xx)
IL (2) IL188330A (xx)
ME (1) ME01513B (xx)
MX (1) MX2007016290A (xx)
NZ (1) NZ565309A (xx)
PE (2) PE20070103A1 (xx)
PL (2) PL1907373T3 (xx)
PT (2) PT2380887E (xx)
RS (2) RS53030B (xx)
SI (2) SI2380887T1 (xx)
WO (1) WO2007005972A1 (xx)
ZA (1) ZA200800828B (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579291C (en) * 2004-09-03 2011-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
JP5366544B2 (ja) 2005-06-30 2013-12-11 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
TW200819435A (en) * 2006-09-15 2008-05-01 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
WO2009111948A1 (zh) * 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN102060746B (zh) * 2009-06-01 2013-02-13 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
RS58523B1 (sr) 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
WO2013126326A1 (en) * 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
US9133161B2 (en) 2012-07-27 2015-09-15 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
KR20150041650A (ko) * 2012-08-09 2015-04-16 셀진 코포레이션 (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 및 이의 약학적으로 허용가능한 형태의 제조를 위한 공정
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
AU2014248263A1 (en) 2013-04-02 2015-10-15 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
CN103232380A (zh) * 2013-05-08 2013-08-07 中国药科大学 一种泊马度胺关键中间体的制备方法
CN103275062B (zh) * 2013-05-17 2016-04-13 宁波百思佳医药科技有限公司 一种Pomalidomide的纯化方法
CN103288797B (zh) * 2013-05-17 2016-03-02 宁波百思佳医药科技有限公司 一种用亚砜类溶剂纯化Pomalidomide的方法
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CN104557858B (zh) * 2013-10-29 2018-06-01 上海医药工业研究院 一种泊利度胺的制备方法
US20160362391A1 (en) 2013-11-25 2016-12-15 Mylan Laboratories Ltd. Improved Process for the Preparation of Pomalidomide and its Purification
CN103724323B (zh) * 2014-01-20 2016-08-17 上海医药工业研究院 泊马度胺的制备方法
CN104016967A (zh) * 2014-04-04 2014-09-03 南京工业大学 一种泊利度胺的合成方法
CN105440013B (zh) * 2014-08-29 2018-10-09 杭州和泽医药科技有限公司 一种泊马度胺的制备方法
WO2016138962A1 (en) 2015-03-05 2016-09-09 Otis Elevator Company Elevator car
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
ITUB20169994A1 (it) 2016-01-14 2017-07-14 Phf Sa Nuove forme cristalline di farmaci immunomodulatori
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
CN106432045B (zh) * 2016-06-29 2018-12-18 深圳海王医药科技研究院有限公司 一种泊马度胺杂质的合成方法
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018154516A1 (en) * 2017-02-23 2018-08-30 Sun Pharmaceutical Industries Limited Process for the preparation of pomalidomide
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
CN111093661B (zh) * 2017-09-07 2023-10-27 化学免疫疗法有限责任公司 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
JP7458324B2 (ja) 2018-04-23 2024-03-29 セルジーン コーポレイション 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用
CN110343063A (zh) * 2019-08-09 2019-10-18 新乡双鹭药业有限公司 一种泊马度胺合成中杂质的制备方法
CN114605381A (zh) * 2020-12-03 2022-06-10 南京海辰药业股份有限公司 一种泊马度胺的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858086A (en) * 1958-09-16 1961-01-04 American Cyanamid Co Method for synthesis of amides of imidazoles or benzimidazoles
US3979416A (en) * 1973-06-15 1976-09-07 Alelio Gaetano F D Preparation of aminophthalic anhydrides
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5637517A (en) * 1995-05-26 1997-06-10 Daewoo Electronics Co., Ltd. Method for forming array of thin film actuated mirrors
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP0925294B3 (en) 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
KR100539030B1 (ko) * 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1064277B1 (en) * 1998-03-16 2005-06-15 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
RU2001121987A (ru) * 1999-03-18 2004-02-27 Селджин Корпорейшн (Us) Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов
DE19942700C1 (de) * 1999-09-07 2001-04-05 Consortium Elektrochem Ind Verfahren zur Herstellung cyclischer N-Hydroxydicarboximide
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP4622016B2 (ja) * 1999-12-20 2011-02-02 東洋インキ製造株式会社 顔料分散剤、顔料組成物および顔料分散体
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
DE60130799T2 (de) * 2000-11-30 2008-07-17 Children's Medical Center Corp., Boston Synthese von 4-aminothalidomid enantiomeren
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
AU2002323063B2 (en) * 2001-08-06 2007-11-08 Entremed, Inc. Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
JP3578752B2 (ja) * 2001-09-28 2004-10-20 三井化学株式会社 水性インク
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
UA83504C2 (xx) * 2003-09-04 2008-07-25 Селджин Корпорейшн Поліморфні форми 3-(4-аміно-1-оксо-1,3-дигідроізоіндол-2-іл)піперидин-2,6-діону$полиморфные формы 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил) пиперидин-2,6-диона
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
NZ550026A (en) * 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
CA2579291C (en) 2004-09-03 2011-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
JP5366544B2 (ja) * 2005-06-30 2013-12-11 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオン化合物を調製するための方法
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
TW200819435A (en) 2006-09-15 2008-05-01 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
MX2010009344A (es) 2008-03-11 2012-09-28 Reddys Lab Ltd Dr Preparacion de lenalidomida.
WO2009111948A1 (zh) 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059106A1 (en) * 2000-12-27 2002-08-01 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof

Also Published As

Publication number Publication date
JP5543555B2 (ja) 2014-07-09
ES2402204T3 (es) 2013-04-29
WO2007005972A1 (en) 2007-01-11
ME01513B (me) 2014-04-20
IL188330A0 (en) 2008-04-13
HRP20130966T1 (hr) 2013-11-22
HK1168851A1 (zh) 2013-01-11
SI2380887T1 (sl) 2013-12-31
US20180044318A1 (en) 2018-02-15
CN101253163A (zh) 2008-08-27
US20140256950A1 (en) 2014-09-11
JP2013014599A (ja) 2013-01-24
AU2006265019B2 (en) 2011-10-13
PT1907373E (pt) 2013-02-18
PE20100151A1 (es) 2010-03-05
RS52704B (en) 2013-08-30
DK1907373T3 (da) 2013-02-04
PE20070103A1 (es) 2007-02-06
CA2823088C (en) 2015-10-06
PL2380887T3 (pl) 2014-01-31
BRPI0612803A2 (pt) 2012-10-02
CA2823088A1 (en) 2007-01-11
CR9697A (es) 2008-06-26
KR101342241B1 (ko) 2013-12-16
HRP20130102T1 (hr) 2013-03-31
CN102643267A (zh) 2012-08-22
US9822093B2 (en) 2017-11-21
JP5366544B2 (ja) 2013-12-11
US9394274B2 (en) 2016-07-19
AU2006265019A1 (en) 2007-01-11
JP2008544993A (ja) 2008-12-11
EP2380887B1 (en) 2013-08-07
US20070004920A1 (en) 2007-01-04
ECSP088154A (es) 2008-03-26
CA2612612C (en) 2014-03-11
RS53030B (en) 2014-04-30
EP1907373B1 (en) 2013-01-09
PT2380887E (pt) 2013-09-18
NZ565309A (en) 2011-03-31
PL1907373T3 (pl) 2013-05-31
KR20080039392A (ko) 2008-05-07
SI1907373T1 (sl) 2013-03-29
ES2430545T3 (es) 2013-11-21
IL214892A0 (en) 2011-10-31
IL214892A (en) 2013-11-28
US7994327B2 (en) 2011-08-09
DK2380887T3 (da) 2013-10-07
US20160297791A1 (en) 2016-10-13
KR20130029442A (ko) 2013-03-22
ZA200800828B (en) 2009-08-26
EP1907373A1 (en) 2008-04-09
HK1121447A1 (xx) 2009-04-24
MX2007016290A (es) 2008-03-10
EP2380887A1 (en) 2011-10-26
CA2612612A1 (en) 2007-01-11
CN102643267B (zh) 2015-09-16
CN101253163B (zh) 2012-05-02
US8785644B2 (en) 2014-07-22
US20110224440A1 (en) 2011-09-15
IL188330A (en) 2013-09-30
US10266514B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
KR101299321B1 (ko) 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온화합물의 제조 방법
JP2008512379A (ja) 置換２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン類の調製方法
JP5265562B2 (ja) イマチニブおよびその中間体の調製方法
JP5805880B2 (ja) １−（４−（４−（３，４−ジクロロ−２−フルオロフェニルアミノ）−７−メトキシキナゾリン−６−イルオキシ）ピペリジン−１−イル）−プロパ−２−エン−１−オン塩酸塩の製造方法および該方法で用いられる中間体
JP4820295B2 (ja) イソインドール誘導体の製造方法
EP2608791B1 (en) A process for the preparation of imatinib base
EP2542530A2 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
JP6777542B2 (ja) 置換尿素化合物の合成のためのプロセス
AU2011221383B2 (en) Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds

Legal Events

Date Code Title Description
A201 Request for examination
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160805

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170808

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180807

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20190806

Year of fee payment: 7